Testicular Gene Expression in Cryptorchid Boys at Risk of Azoospermia

F. Hadziselimovic^{a, b} N.O. Hadziselimovic^{b, c} P. Demougin^c E.J. Oakeley^d

^aChildren's Day Care Clinic Liestal, ^bInstitute of Andrology, Liestal, ^cBiozentrum, University of Basel, and

^dNovartis Institutes for Biomedical Research, Basel, Switzerland

Key Words

Ad spermatogonia • Affymetrix • Azoospermia • Cryptorchidism • Gene expression • Testis

Abstract

Despite timely and successful surgery, 32% of patients with bilateral and 10% with unilateral cryptorchidism will develop azoospermia. Cryptorchid boys at risk of azoospermia display a typical testicular histology of impaired mini-puberty at the time of the orchidopexy. During mini-puberty increased gonadotropin and testosterone secretion stimulate transformation of gonocytes into Ad spermatogonia. In the azoospermia risk group this transformation is to a great extent impaired. This study aimed to analyze data on whole genome expression signatures of undescended testes at risk of developing azoospermia. Twenty-three testicular biopsies from 22 boys were analyzed (19 testes from 18 boys with cryptorchidism and 4 contralateral descended testes from patients with testicular agenesis). Expression profiling identified 483 genes not or under-expressed in the azoospermia risk group compared with the control and low risk for azoospermia (LAZR) groups. Annotated loci were associated with spermatogenesis. Other significant genes were cellular defense response genes and hormone-controlled loci involved in spermatogenesis. Some genes transcribed in normal adult meiotic and post-meiotic germ cells are activated

in healthy juvenile Ad spermatogonia. Thus, molecular events initiating the testicular expression program at the onset of puberty and maintaining it during adulthood occur very early in prepubertal testes. This molecular event is to a great extent impaired in the high risk for azoospermia (HAZR) group lacking Ad spermatogonia (stem cells for spermatozoa) indicating impaired mini-puberty.

Copyright © 2011 S. Karger AG, Basel

Cryptorchidism is among the most common birth defects in humans and is one of the main etiologic causes of non-obstructive azoospermia in man. Twenty-seven (60%) of 45 men with otherwise unexplained non-obstructive azoospermia had a history of cryptorchidism [Fedder et al., 2004]. The main reasons for treating this pathology are to prevent development of infertility during adulthood and to decrease the risk of testicular cancer. However, despite successful orchidopexy, spermatogenesis ultimately may be dramatically impaired in a subgroup of patients showing disturbed testicular maturation during the period of mini-puberty, with as many as 20% developing azoospermia [Hadziselimovic and Herzog, 2001; Hadziselimovic et al., 2007]. A reliable indicator of this maturation process is the presence of Ad spermatogonia located in prepubertal testis [Seguchi and Hadziselimovic, 1974]. These cells display dark (electron-dense)

cytoplasm and a bright spot within the nucleus that distinguishes them from fetal and A pale (Ap) spermatogonia [Seguchi and Hadziselimovic, 1974; Nistal and Paniagua, 1984; Paniagua and Nistal, 1984]. A surge in gonadotropin and testosterone levels during early postnatal development (mini-puberty) is required for the differentiation of gonocytes into Ad spermatogonia, a process that is proposed to be essential for normal adult fertility [Hadziselimovic et al., 1986, 2005; Hadziselimovic and Zivkovic, 2007].

Endocrine or primary end organ failure are 2 different etiological factors thought to be responsible for the increased incidence of azoospermia and subfertility in unilateral as well as bilateral cryptorchidism [Hadziselimovic et al., 1979, 2004, 2005; Job et al., 1987; Cortes et al., 1996; Gracia et al., 2000; Hamza et al., 2001; Toppari et al., 2007]. In this study, data from whole-genome expression signatures of undescended testes lacking Ad spermatogonia and at risk of developing azoospermia are provided and analyzed in the context of data obtained from descended and cryptorchid testes with Ad spermatogonia.

Patients and Methods

Testicular Biopsies and Pooling of Patients

At our institution, it is routine practice to perform testicular biopsy during surgery for undescended testis. We find that testicular biopsy provides useful information about future semen quality and helps identify patients with atypical spermatogonia or carcinoma in situ.

Cryptorchid testis is defined as a testis localized outside the scrotum and incapable of being brought into a stable scrotal position. Twenty-three rice-grain-large testicular biopsies from 22 boys were analyzed (19 testes from 18 boys with cryptorchidism and 4 contralateral descended testes from patients with testicular agenesis). Not all contralateral testes in patients with testicular agenesis are expected to have normal histology and may require subsequent hormonal treatment [Huff et al., 1991]. Therefore, we routinely biopsy these testes during the period of testicular fixation performed to prevent testicular torsion. All contralateral testes were selected for normal histology according to age. The mean age of the patients at surgery was 3.4 (95% CI 0.6–6.1) years and 3.9 (95% CI 2.3–5.4) years for the controls. All patients had an extensive clinical examination. We could not find any clinical signs of developmental malformations or syndromes, and none had hypospadias. In particular no clinical sign for Kallmann syndrome was observed. Furthermore, all patients had normal thyroid screening and no features of hypopituitarism were discernible. Biopsies were fixed in 3% glutaraldehyde and embedded in Epon. Semi-thin 1- μ m-thick sections were examined by Zeiss Axio-scope phase-contrast and conventional light microscopy (Plan-Apochromat 63 $\times$ /1.40 oil). An aliquot of each biopsy fraction, flash frozen into liquid nitrogen and stored at -80°C , was fixed

in PBS containing 1% formaldehyde (Polio, France) and 1% fetal calf serum (Eurabbie, France) and analyzed by DNA flow cytometry to determine its relative DNA content. An aliquot was processed with Affymetrix target synthesis kits currently available for 3' IVT arrays. Amplifications were based upon T7 RNA polymerase using oligo-dT priming and the same arrays were used to minimize variability. Cell pellets and tissues were sheared in RLT buffer (Qiagen) supplemented with 1% β -mercaptoethanol from which aqueous phases were taken out for RNA isolation. Total RNA isolation was performed using RNeasy Mini Kit according to standard protocols. RNA quality was monitored using RNA Nano 6000 Chips and the 2100 BioAnalyzer (Agilent). Targets were synthesized using the Affymetrix One-Cycle cDNA Synthesis Kit or Affymetrix 3' IVT Express Kit. Following quality-check on BioAnalyzer, targets were hybridized onto GeneChip Human Genome U133 Plus 2.0 Arrays at 45°C for 17 h. Arrays were washed on a Fluidics Station 450 (Affymetrix) using the Hybridization Wash and Stain Kit (Affymetrix) and the Washing Procedure FS450_0007. Arrays were scanned on a Scanner 3000 7G (Affymetrix) and CEL files generated by AGCC software (Affymetrix). Raw data files are available at the EBI ArrayExpress repository [Parkinson et al., 2007] via the accession numbers E-TABM-130 and E-TABM-174 and GEO (GSE25518).

Statistical Analysis and Interpretation of Microarray Data

The data analysis and gene filtering was performed using R/Bioconductor [Gentleman et al., 2004]. Signal condensation was performed using only the RNA from the Bioconductor Affy package. Differentially expressed genes were identified using the Benjamin-Hochberg false discovery rate correction implemented in the LIMMA package and adjusted with the False Discovery Rate (FDR) method [Wettenhall and Smyth, 2004]. We selected these probe sets with a $\log_2$ average contrast signal of at least 5, an adjusted p value <0.05 , and an absolute $\log_2$ -fold change of >0.585 (1.5-fold in linear space). Hierarchical clustering and visualization was performed in R. The minimum number of genes in a cluster associated with a given annotation term was set at ≥ 3 . BioGRID, MINT, and IntAct (PSI MI 2.5 format) interactome data sets were uploaded and combined into AMEN. To improve gene annotation and interactome information, mouse, rat, and human protein entries were combined and converted into Homologous Gene identifiers [Wheeler et al., 2007]. A data set containing gene identifiers and corresponding expression values was uploaded into the application. Gene lists from the resulting contrasts were further classified into regulatory networks and pathways with Ingenuity Pathways Analysis (Ingenuity Systems, www.ingenuity.com). Each gene identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base.

These genes, called focus genes, were overlaid into a global molecular network developed from information contained in the Ingenuity Pathways Knowledge Base. Networks of these focus genes were then algorithmically generated based on their connectivity. Functional analyses associated with biological functions and/or diseases in the Ingenuity Pathways Knowledge Base were considered, and Fisher's exact test was used to calculate a p value, determining the probability that each biological function and/or disease assigned to that data set is due to chance and chance alone.

Fig. 1. Immunohistochemical staining for MAGEA4 in the LAZR group. In all cases antibody binding was visualized using peroxidase as a substrate to generate brown color. Sections were counterstained with toluidine blue. sp: Immunopositive spermatogonia. Horizontal bar = 0.1 mm.

Quantitative Real-Time PCR

Quantitative real-time PCR (qRT-PCR) was performed using a Corbett Research RG-6000 instrument. cDNAs were synthesized with the Reverse Transcriptase Core Kit (Eurogentec, cat# RT-RTCK-03) using random primers [Hadziselimovic et al., 2009]. Real-time PCR runs were performed using SYBR Fast Kit (Kapa Biosystems, cat# KK4602) with each gene-specific primer at 200 nM final concentration in a total volume of 17.5 μ l. Wave lengths for source and detection were set at 470 and 510 nm, respectively. Gain was set at 8.33. The PCR program was set as follows: 95°C for 60 s, then 45 cycles at 95°C for 3 s, 60°C for 10 s, and 72°C for 4 s followed by a melting curve analysis (65°C to 95°C, rising by 0.65°C during each step) to attest to amplification specificity. Threshold cycles (crossing point) were determined using Rotor-Gene software version 6.1. Good PCR efficiency was checked by performing a dilution series of the cDNA. Minus RT controls were performed for each sample studied. Threshold cycles (crossing point) were determined using Rotor-Gene software version 6.1. Expression levels were normalized to *TFRC* and *GAPDH* using the geometric mean of their level of expression. These genes were selected because they showed the smallest variation between individual samples (both on microarrays and by qPCR). Fold differences were calculated using the Δ Ct method (online supplement figure 1; for all online supplement material, see www.karger.com/doi/10.1159/000323955).

Antibody Validation

For immunohistochemical analysis, the Epon was removed from the tissue sections. The sections were treated with 2% bovine serum albumin to reduce non-specific binding and then incubated with the primary antibody overnight at 4°C. All samples were washed with PBS between incubations. We validated 8 antibodies: DDX25, EGR1, EGR4, CBL, ALDH1A2, KLF4, MAGEA4, and COL4A3 (fig. 1–3, online suppl. table 1). Secondary antibodies,

labeled with horseradish peroxidase-polymer (HRP; goat polyclonal anti-rabbit IgG, mouse IgG and IgM, prediluted ab2891, Abcam, Cambridge, UK) were used to detect the binding of the primary antibody. The chromogenic reaction was developed by adding a freshly prepared solution of 3,3-diaminobenzidine solution (DAB + chromogen; DAKO). The DAB reaction was terminated by washing in Tris-buffered saline (0.05 M TBS and 0.85 M NaCl, pH 7.6). To visualize the histology of testicular cells, the samples were counterstained with toluidine blue. Antibody binding was indicated by a brown precipitate. Different cell types were identified based on their nuclear morphology and position within the developing gonad. Immunohistochemistry experiments were performed at least twice on at least 4 patients from each group, and only those with identical results between experiments for each sample were considered acceptable. Controls for non-specific binding of the secondary antibody were performed in all experiments by omitting the primary antibody; these consistently yielded no signal within the seminiferous epithelium or the interstitial space. The interstitial staining observed in the presence of the primary antibody was considered to be nonspecific because it was not associated with, or localized within, a particular cell type. However, staining of interstitial cells was recorded.

Experimental design, biomaterials and treatments, reporters, staining, imaging data, and image characterization were performed in compliance with the minimum information specification for immunohistochemistry experiments [Deutsch et al., 2008].

Ethical Considerations and Approval

In accordance with the Declaration of Helsinki, the Institutional Review Board and the Independent Ethics Committee of the Children's Clinic Liestal approved all aspects of this study. Approval was provided for research involving the use of material (data records or biopsy specimens) that had been collected for non-research purposes.

Fig. 2. Immunohistochemical COL4A3 staining in the HAZR group. Immunonegative tubules for COL4A3 contain Sertoli cells only (se). Background staining was performed with toluidine blue. Scale bar = 0.1 mm.

Fig. 3. Immunohistochemical COL4A3 staining in the control group. Germ cells localized at the basement membrane are stained brown (sp). Background staining was performed with toluidine blue. se: Sertoli cell. Scale bar = 0.1 mm.

Results

An Expression Signature Distinguishes High Azoospermia Risk from Control Patients

Total RNA and cRNA samples were of high quality and the signal intensity distributions were similar and within the normal range. Our statistical filtration strat-

egy identified 483 transcripts differentially expressed between the azoospermia risk group and control patients, and 370 transcripts differentially expressed between the high risk for azoospermia (HAZR) and low risk for azoospermia (LAZR) groups (fig. 4). Notably, 62 genes involved in germ cell development were equally expressed in the LAZR and control groups, whereas 46/62 genes

Fig. 4. Heat map (unsupervised) showing hierarchical clustering of gene expression profiles.

were not and 16/62 genes were expressed at lower levels in the HAZR group (table 1).

Furthermore, 18/27 genes proposed as being involved in A spermatogonia self-renewal [Wu et al., 2009] were not expressed in the HAZR group, but were expressed in the LAZR and control groups (online suppl. table 2). Nei-

ther *GDNF* (glial cell-derived neurotrophic factor) nor its regulatory genes, *BHLHB2* (basic helix-loop-helix domain containing, class B, 2), *LHX1* (LIM homeobox 1), *GFRA1* (GDNF family receptor alpha 1), and *TEC* (Tec protein tyrosine kinase), were found to be expressed in all groups studied. Compared with controls, we found that

Table 1. Transcript signature of differentially expressed genes involved in germ cell development in the high (HAZR) and the low azoospermia risk (LAZR) group as well as in the control group

Gene	ID	HAZR	LAZR	Control	adjusted p		Approved gene name
					HAZR/con.	HAZR/LAZR	
ALDH1A1	207 016 s-at	4.53	6.88	7.0	0.007	0.0006	aldehyde dehydrogenase 1 family, member A1
AMPH	205 239 at	3.42	4.67	5.33	0.01	0.02	amphiphysin
CACNA2D2	204 811 s-at	5.63	6.95	6.85	0.01	0.0007	calcium channel, voltage-dependent, alpha 2/delta subunit 2
CBL	225 234 at	6.9	7.88	8.21	0.003	0.0004	Casitas B-lineage lymphoma
CDC20	202 870 s-at	3.79	5.82	6.11	0.01	0.003	cell division cycle 20 homolog (<i>S. cerevisiae</i>)
CLGN	205 830 at	4.51	5.54	5.83	0.01	0.01	calmegin
CSRP2	207 030 s-at	5.83	7.54	7.38	0.02	0.002	cysteine and glycine-rich protein 2
CXCL9	203 915 at	4.49	6.07	6.03	0.009	0.0007	chemokine (C-X-C motif) ligand 9
DAZ1	207 912s-at	3.55	4.35	5.14	0.008	n.s.	deleted in azoospermia 1
DAZL	206 588 at	6.81	7.67	7.85	0.04	0.03	deleted in azoospermia-like
DDX25	219 945 at	4.39	5.86	5.74	0.02	0.001	DEAD (Asp-Glu-Ala-Asp) box polypeptide 25
DDX4	221 630 s-at	3.47	7.05	7.43	0.002	8.25E-05	DEAD (Asp-Glu-Ala-Asp) box polypeptide 4
DMRTB1	240313 at	4.29	5.87	5.93	0.009	0.003	DMRT-like family B with proline-rich C-terminal, 1
DPYSL4	205 493 s-at	3.8	5.49	5.26	0.01	0.001	dihydropyrimidinase-like 2
DTL	218 585 s-at	5.04	6.5	6.5	0.008	0.0007	denticleless homolog (<i>Drosophila</i>)
DUSP5	209 457 at	5.77	7.38	7.7	0.03	0.008	dual specificity phosphatase 5
EGR4	207 768 at	2.7	5.65	5.91	0.007	0.006	early growth response 4
ESX1	155 2445 a-a	3.46	6.48	6.75	0.01	8.63E-05	ESX homeobox 1
FGF9	206 404 at	4.64	5.97	5.75	0.01	0.0001	fibroblast growth factor 9 (glia-activating factor)
FGFR3	204 379 s-at	4.52	8.6	8.65	0.003	0.0001	fibroblast growth factor receptor 3
FOXP1B	206 018 at	3.41	5.88	5.81	0.001	1.21E-05	forkhead box G1b
FST	204948 s-at	5.53	6.42	6.76	0.003	0.001	folliculin
GTSF1	227711 at	4.62	7.27	6.9	0.01	0.0001	gametocyte-specific factor 1
GAGE1	207 086 x-at	5.59	9.13	10.04	0.003	0.001	G antigen 1
ID4	209 291 at	5.19	7.6	8.37	0.001	0.0002	inhibitor of DNA binding 4, dominant negative helix-loop-helix protein
ISL1	206104 at	3.53	5.68	6.22	0.003	0.0004	ISL LIM homeobox 1
KIF21B	204 411 at	4.34	5.7	5.65	0.006	0.0001	kinesin family member 21B
LIN28B	229 349 at	3.54	5.27	5.87	0.01	0.01	lin-28 homolog B (<i>C. elegans</i>)
LIN7B	246 290 x-at	4.57	5.78	6.1	0.03	0.02	lin-7 homolog B (<i>C. elegans</i>)
MAGEA4	214 254 at	3.78	5.95	6.53	0.006	0.009	melanoma antigen family A, 4
MAGEC1	206 609 at	3.8	6.77	6.92	0.001	8.24E-05	melanoma antigen family C, 1
MBD2	214 397 at	4.25	7.44	7.65	0.003	0.03	methyl-CpG-binding domain protein 2
MND1	223 700 at	2.89	5.29	5.23	0.03	0.004	meiotic nuclear divisions 1 homolog (<i>S. cerevisiae</i>)
MORC1	220 850 at	3.49	5.26	5.55	0.01	0.0001	MORC family CW-type zinc finger 1
NLRP2	221 690 s-at	4.3	6.18	5.86	0.04	0.005	NLR family, pyrin domain containing 2
NMU	206 023 at	4.12	6.08	5.98	0.03	0.005	neuromedin U
NRG1	206 343 s-at	3.55	5.13	5.28	0.03	0.004	neuregulin 1
PIWIL2	231 371 at	5.1	6.88	6.47	0.002	0.0001	piwi-like 2 (<i>Drosophila</i>)
PIWIL4	230 480 at	4.7	7.15	7.57	0.001	0.0001	piwi-like 4 (<i>Drosophila</i>)
RBMY1A1	208 307 at	4.39	6.45	6.37	0.008	0.0008	RNA binding motif protein, Y-linked, family 1, member A1
RGST7	206 290 s-at	2.76	5.27	5.39	0.01	0.001	regulator of G-protein signaling 7
RNF17	220 270 at	4.17	5.40	5.83	0.01	0.01	ring finger protein 17
SH3GL2	205 751 at	5.41	6.49	6.74	0.02	0.008	SH3-domain GRB2-like 2
SIX1	228 347 at	3.93	6.98	6.55	0.01	0.02	SIX homeobox 1
SNAP91	204 953 at	4.22	5.4	6.0	0.006	0.008	synaptosomal-associated protein, 91 kDa homolog (mouse)
SNRP	226587 at	8.79	9.09	10.3	0.04	n.s.	U1 snrp Snp1p. RRM domain containing protein
SOX30	207 678 s-at	3.13	5.20	6.02	0.002	0.002	SRY (sex-determining region Y)-box 30
SRY	207678 s-at	3.1	5.2	5.8	0.002	0.002	sex-determining region Y
SPA17	205 406 s-at	4.3	6.02	6.18	0.02	0.01	sperm autoantigenic protein 17
SSX2	207 493 x-at	3.77	5.65	6.42	0.03	0.003	synovial sarcoma, X breakpoint 2
SYCP3	155 3599a-a	3.59	5.18	5.57	0.02	0.0002	synaptonemal complex protein 3
TAF5	210 053 at	6.92	7.91	8.08	0.02	0.005	TAF5 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 100 kDa
TAF7L	220 325 at	3.72	5.02	5.48	0.01	0.03	TAF7-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 50 kDa
TDRD10	231 371 at	4.68	5.38	5.69	0.01	n.s.	tudor domain containing 10
TDRD5	231 104 at	3.78	4.92	5.36	0.01	0.01	tudor domain containing 5
TDRD6	232 692 at	5.1	6.79	7.26	0.001	0.0003	tudor domain containing 6
TDRD9	118 285 at	4.75	6.52	6.92	0.01	0.009	tudor domain containing 9
TEX14	221035 s-at	3.58	5.46	5.67	0.008	0.001	testis expressed 14
TLE1	228 284 at	5.48	7.24	7.47	0.01	0.0001	transducin-like enhancer of split 1 (E(sp1) homolog, <i>Drosophila</i>)
TSPY1	207 918 s-at	5.03	9.98	10.28	0.001	8.24E-05	testis-specific protein, Y-linked 1
UFT1	208 275 x-at	3.61	5.59	5.71	0.003	0.0002	undifferentiated embryonic cell transcription factor 1
WNT3	229 103 at	2.98	5.16	4.65	0.03	0.0003	wingless-related MMTV integration site 3

Genes interacting with hypothalamus-pituitary-testicular axis are indicated in bold. The limit of the essay detection is 5.

204 transcripts were more highly expressed in the HAZR group, whereas only 8 were more highly expressed in the LAZR group. Most of the over-expressed genes in the HAZR group were related to cell growth and proliferation as well as to apoptosis. In the azoospermia risk group, expression profiling identified genes not expressed or expressed at significantly lower levels at loci associated with spermatogenesis and testicular development, including *CBL*, *CDC20*, *DAZ1/2/3/4*, *DAZL*, *ESX1*, *LIN28B*, *MBD2*, *RBMY1A1*, *SRY*, *TAF5*, *TAF5L*, *TDRD5/6/9/10*, *TSPY1*, *UTF1* (table 1). Other significantly down-regulated genes included: cellular defense response genes *CXCL9*, G antigen family members (*GAGE*), *NLRP2*, brain/pituitary development genes; *ISL1*, *NMU*, *NRG1*, *SIX1*, *TLE1* and hormone-controlled loci known to be involved in spermatogenesis; *DDX25*, *DDX4*, *DUSP5*, *EGR4*, *FGFR3*, *FGF9*, *ID4*, *NMU*, *NRG1*, *SYCP3*, *SPA17*, and *TLE7L*. We identified transcripts not expressed in the HAZR group that are specific for mitosis (*MORC1*) and meiosis (*MND1*, *GTSF1*, *PIWIL2/4*, *RNF17*, *SOX30*, *SYCP3* and *TAF5*) of germ cell lines (table 1). Recently, 6 genes were proposed to be specific biomarkers of adult human spermatogonia: fibroblast growth factor receptor 3 (*FGFR3*), desmoglein 2 (*DSG2*), E3 ubiquitin ligase c-CBL (casitas B-cell lymphoma), cancer/testis antigen NY-ESO-1 (*CTAG1A/B*), undifferentiated embryonic cell transcription factor 1 (*UTF1*), and synaptosomal-associated protein, 91-kDa homolog (*SNAP91*) [von Kopylow et al., 2010]. We found that all 6 genes were expressed in the prepubertal spermatogonia in the control and LAZR groups. In the HAZR group the transcription profile was altered; 2 genes, *DSG2* and *CTAG1A*, were equally expressed, whereas *CBL* and *SNAP91* were under-expressed and *FGFR3* and *UTF1* were not expressed (table 1).

HIR-Signature Genes Encode Factors That Directly Interact with Each Other

To further explore and extend the RNA profiling data, we next investigated if genes differentially expressed in the azoospermia risk group and in control patients encode proteins that are physically associated with other factors. Information on direct protein-protein interactions was retrieved from the BioGRID, MINT, and IntAct databases and processed using AMEN [Stark et al., 2006; Chatranyamontri et al., 2007; Kerrien et al., 2007]. We found 2 interaction networks comprising 9 genes (*AMPH*, *CACNA2D2*, *CSRP2*, *DPYSL4*, *KIF21B*, *LIN7B*, *RGS7*, *SH3GL2*, and *SNAP91*) and 4 genes (*TLE1*, *DTL*, *FOXG1B* and *SIX1*), respectively. The proteins in this group were associated with diverse biological processes including

microtubule-based movement and mitosis (*KIF2C*, *KIF21B*) and signal transduction (*LIN7B*, *RGS7*, *SH3GL2*). Proteins in the smaller complexes were annotated as DNA-dependent regulators of transcription (*TLE1*, *SIX1*, *FOXG1B*, *SSX2*) or proteins involved in DNA replication (*DTL*). We also identified a cancer/testis gene (*MAGEC1*) whose hallmark is to be actively transcribed in the germ line, repressed in normal somatic tissues, and de-repressed in various cancers [Simpson et al., 2005]. Finally, we found the *BRAF* gene which encodes a protein belonging to the raf/mil family of serine/threonine protein kinases to be under-expressed in the HAZR group. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and has a key role in transcriptional activation of GnRH-responsive genes. The third interaction network includes the *DAZ* (deleted in azoospermia) gene family (table 1). Proteins in this group are associated with spermatogenesis development and function. Furthermore, no testicular expression of *CDC20*, *ESX1*, *RBMY1A1* and *SYCP3* genes involved in azoospermia development were observed in the HAZR group (table 1).

Immunohistochemical and qRT-PCR Validation

We wanted to determine whether greater transcript expression corresponded with greater protein expression. Immunoperoxidase histochemistry, although not a quantitative method, is currently the only practical way to detect proteins in small fixed tissue samples. Identical cytoplasmic localization was found for all proteins analyzed (fig. 1–3). In addition to their expression in germ and Leydig cells, we found that the *CBL* gene was also expressed in Sertoli cells. Finally, we validated our microarray data by qRT-PCR for 4 genes that showed significant expression changes; all of these showed a high correlation with the obtained transcriptional profiles (online suppl. fig. 1).

Discussion

The estimated frequency of azoospermia in the normal population is 0.4% (3/711) [Itoh et al., 2001]. Despite successful surgery, azoospermia was found 25 times more often in unilateral and 80 times more often in bilateral cryptorchidism (table 2). Thus cryptorchidism represents one of the most frequent causes of azoospermia in man. Furthermore, according to the testicular histology, 50% of cryptorchid patients in our cohort belonged to the high azoospermia risk group [Hadziselimovic et al., 2007]. Absence of Ad spermatogonia was a typical pathological

Table 2. Incidence of azoospermia in unilateral and bilateral cryptorchid males

Reference	Unilateral cryptorchid			Bilateral cryptorchid		
	Untreated	HCG	Surgery	Untreated	HCG	Surgery
Hansen, 1949	1/35 (3%)		3/37 (8%)	9/9 (100%)		14/25 (56%)
Scott, 1961			5/38 (13%)			
Eisenhut and Hohenfellner, 1964			7/34 (20%)			
Canlorbe et al., 1966		15/100 (15%)	28/111 (25%)		22/59 (37%)	38/87 (44%)
Madersbacher et al., 1972			5/36 (14%)			
Czaplicki et al., 1974					5/13 (38%)	5/13 (38%)
Bramble et al., 1974						5/21 (24%)
Richter et al., 1976		4/43 (9%)	1/28 (3%)		9/35 (26%)	8/15 (53%)
Kleinteich et al., 1976			8/66 (12%)			5/34 (15%)
Werder et al., 1976						6/14 (43%)
Giarola and Agostini, 1979	15/99 (15%)		12/108 (11%)	10/10 (100%)		
Guillon, 1979		6/55 (11%)	15/105 (14%)		10/35 (29%)	22/87 (25%)
Wojciechowski et al., 1979			10/106 (9%)			16/24 (66%)
Duvie, 1984			1/10 (10%)			22/48 (46%)
Ponchietti and Grechi, 1986			8/104 (8%)			
Puri and O'Donnell, 1988			4/119 (3%)			
Okuyama et al., 1989			10/37 (27%)			
Mandat et al., 1994			12/112 (11%)			2/23 (9%)
Taskinen et al., 1996			0/39 (0%)			3/12 (25%)
Cortes et al., 1996			2/56 (4%)			
Gracia et al., 2000			8/196 (4%)			5/55 (9%)
Paasch et al., 2004			17/130 (13%)			11/37 (30%)
Hadžiselimović et al., 2004			16/182 (9%)			
Moretti et al., 2007			4/30 (13%)			3/12 (25%)
Trsinar and Muravec, 2009			2/49 (4%)			2/19 (10%)
	16/134 (12%)	25/198 (12.6%)	178/1733 (10.3%)	19/19 (100%)	46/142 (32%)	167/526 (32%)

finding for this group of patients. During testicular maturation, gonocytes from cryptorchid boys undergoing abnormal mini-puberty fail to differentiate into Ad spermatogonia [Hadžiselimovic and Herzog, 2001; Hadžiselimovic et al., 2007; Hadžiselimovic and Hoecht, 2008]. This developmental process requires increased gonadotropin and testosterone secretion [Hadžiselimovic et al., 1986, 2005]. Several different physiological functions have been attributed to mini-puberty [Hutanhemi, 2003]. Our findings, however, suggest that the male fertility potential is established during this period [Hadžiselimovic et al., 2005]. Furthermore, analyzing the whole genome expression profiling of testicular tissue, we found that cryptorchid boys lacking Ad spermatogonia had decreased expression of most of the genes essential for hypothalamo-pituitary-testicular axis function (table 1). In particular, *EGR4*, which is involved in regulating the secretion of luteinizing hormone, was virtually silent in the HAZR group [Hadžiselimovic et al., 2009].

In the present study, the whole genome expression profiling analysis of prepubertal Ad-positive spermatogonia (Ad+) and Ad-negative spermatogonia (Ad-) testes yielded the unexpected result that several genes important for the meiotic and post-meiotic stages of spermatogenesis can be detected in Ad+ prepubertal testes but not in Ad- samples. A critical question arises as to which cell types express the mRNAs identified as being present in Ad+ but not in Ad- testes.

One would expect transcripts that are missing in samples from the azoospermia risk group patients to be predominantly expressed in Ad spermatogonia because these cells are absent in gonads with this pathology. Indeed, we found that a large group of genes for which no mRNA is detected in Ad- samples show peak expression in the LAZR as well as in the control testis group (table 1). Thus, it is conceivable that some of the molecular events initiating the testicular expression program at the onset of puberty and maintaining it during adulthood actually take place very early in prepubertal testes.

Moreover, 6 genes proposed to be specific biomarkers of adult human spermatogonia [von Kopylow et al., 2010] were expressed in the prepubertal Ad+ testes, while 4 genes were lacking or had lower expression in Ad- testes. This is further evidence that molecular events initiating the testicular expression program at the onset of puberty take place very early in infant testes, and that this program is impaired in the HAZR group.

We observed that many of the genes for which transcriptional activity was detected in Ad+ but not in Ad- testes are implicated in spermatogenesis and fertility. This group includes *MORC1*, encoding an ATPase-like protein required for the transition through meiosis [Watson et al., 1998; Inoue et al., 1999], *CLGN*, a factor required for sperm function [Ikawa et al., 2001], and the transcriptional inhibitor *ID4*, which was shown to be FSH- or cAMP-inducible in Sertoli cells [Norton et al., 1998; Chaudhary et al., 2001] as well as the tudor (*TDRD*) genes, which are also necessary for gametogenesis and rule the PIWI-interacting RNA pathway, helping to maintain the integrity of the genome and the development of the germ cells [Siomi et al., 2010] (table 1). Noticeably, expression of *Tdrd5* was absent in testes isolated from We/We mouse embryos, which completely lack germ cells [Smith et al., 2004]. Furthermore, a group of genes was identified that appear not to be expressed in juvenile Ad- gonads, although they display peak transcription in adult Sertoli cells. Since both Ad+ and Ad- gonads contain juvenile Sertoli cells, the differences might be caused by an absence of spermatogonia in SCO-type gonads or, more likely, impaired maturation of Sa-type Sertoli cells. It is noteworthy that this group includes *DUSP5*, a member of the dual-specificity protein phosphatase subfamily involved in MAP kinase and IL-2 signaling, the cell cycle and cell adhesion as well as influencing GnRH effect [Kovanen et al., 2003; Jeong et al., 2007; Armstrong et al., 2009], and *DMRTB1* from the DMRT family (doublesex and mab-3 related transcription factor) involved in the regulation of postnatal testis differentiation [Raymond et al., 2000]. The important testis developmental gene *SRY* (sex-determining region of Y chromosome), implicated in sexual development of the reproductive system and specification of Sertoli and Leydig cell lineages [Barsoum and Yao, 2006], was not expressed in the HAZR group (table 1). Furthermore, genes known to be essential for mouse stem cell self-renewal such as *Ret*, *Gfra1* and *Bcl6b* were more highly expressed in human prepubertal spermatogonia than in somatic cells [Wu et al., 2009]. A hypothesis was proposed that glial cell line-derived neurotrophic factor (GDNF) is essential for human stem cell (A spermatogonia) renewal [Wu et al., 2009].

Neither *GDNF* nor its regulatory genes *BHLHB2*, *LHX1*, *GFRA1*, and *TEC* were expressed in all groups studied. Additionally, 2 regulatory genes, *BCL6B* and *RET*, were equally expressed in all 3 groups. This contradictory observation may result from the different methods utilized: analysis of isolated germ cells versus in situ analysis. The strength of the current study is that spermatogonia were analyzed directly in their cognate microenvironment. Thus, our result seriously questions the hypothesis of GDNF-driven regulation of human Ad spermatogonia self-renewal.

Microdeletions of the long arm of the Y chromosome (Yq) involving 3 azoospermia factor (AZF) loci, AZFa, AZFb, and AZFc, represent one of the main molecular determinants of male infertility, and account for about 10% of cases of non-obstructive azoospermia or severe oligozoospermia [Stuppia et al., 1998]. The most frequent deletion of the Y chromosome is AZFc, b2/b4 [Kuroda-Kawaguchi et al., 2001]. However, among the 32 men with a history of cryptorchidism, only 1 had Y microdeletions [Fedder et al., 2004]. This result is consistent with additional studies in which it was not possible to detect Y microdeletions in any of 66 men treated for cryptorchidism in childhood [Fagerli et al., 1999; Vutyavanich et al., 2007]. Therefore, Y microdeletions as a cause of azoospermia in cryptorchidism are rather unlikely.

Among the deleted genes involved in azoospermia development, the main candidates for spermatogenesis failure are the *DAZ* gene, a testis-specific gene present in 4 copies within AZFc, encoding an RNA-binding protein, and the *RBMV* gene, which is declared to be the major AZFb gene [Yen, 2004; Vogt et al., 2005]. Furthermore, the cell division cycle molecule *CDC20* was found to be down-regulated in azoospermic testes [Yang et al., 2009]. Azoospermia associated with a decrease in *DAZ* gene function in humans may, in part, be a consequence of failure at synapses caused by reduced levels of SYCP3 protein [Reynolds et al., 2007]. We found that specimens from the azoospermia risk group did not exhibit *CDC20*, *DAZ1,2,3,4/DAZL*, *RBMV1A1*, and *SYCP3* gene expression (table 1). Recently, up-regulated expression of the *EGR4* gene was described in azoospermic men with AZFc deletion and lack of *DAZ* gene expression [Gatta et al., 2010]. The observed lack of *DAZ1* and *EGR4* gene expression in the HAZR group implies that the *EGR4* gene functions as an upstream regulator of the *DAZ/DAZL* gene pathway. It should be emphasized that prepubertal treatment of boys at risk for azoospermia and infertility (aged 6–36 months) with busserelin (luteinizing hormone releasing hormone analogue) restored full fertility in 86% of the cases (none had azoospermia), whereas all boys re-

ceiving surgery who were not treated became oligospermic, and 20% developed azoospermia [Hadziselimovic, 2006]. These data are in keeping with hypogonadotropic hypogonadism being critically involved in cryptorchidism [Hadziselimovic et al., 1986, 2004, 2009; Job et al., 1987; Hamza et al., 2001] and argue against primary testicular failure (testicular dysgenesis) [Cortes et al., 1996; Gracia et al., 2000; Toppari et al., 2007; Virtanen et al., 2007] as the major cause of azoospermia and infertility.

Taken together, our results support the notion that azoospermia and infertility induced by cryptorchidism

are predominantly an endocrine disease of impaired mini-puberty rather than the mutation of the *CDC20*, *DAZ/DAZL/SYCP3* or *RBMY/RBMY1A1* genes. Finally, we present additional evidence that molecular events initiating the adult testicular expression program, occurring very early in prepubertal testes, were abnormal in cryptorchid boys at risk for azoospermia development. Thus, we found a transcript expression signature that distinguishes the high azoospermia and the low azoospermia risk groups.

References

- Armstrong SP, Caunt CJ, McArdle CA: Gonadotropin-releasing hormone and protein kinase C signaling to ERK: Spatiotemporal regulation of ERK by docking domains and dual-specificity phosphatases. *Mol Endocrinol* 23:510–519 (2009).
- Barsoum I, Yao HH: The road to maleness: from testis to Wolffian duct. *Trends Endocrinol Metab* 17:223–228 (2006).
- Bramble FJ, Houghton AL, Eccles S, O'Shea A, Jacobs HS: Reproductive and endocrine function after surgical treatment of bilateral cryptorchidism. *Lancet* 10:311–314 (1974).
- Canlorbe P, Gothié S, Guillon G, Lange JC: Cryptorchidism (Study of 145 cases). VI. Prognosis. *Ann Pediatr (Paris)* 13:270–274 (1966).
- Chatranyamontri A, Ceol A, Palazzi LM, Nardelli G, Schneider MV, et al: MINT: the Molecular INTeraction database. *Nucleic Acids Res* 35:572–574 (2007).
- Chaudhary J, Johnson J, Kim G, Skinner MK: Hormonal regulation and differential actions of the helix-loop-helix transcriptional inhibitors of differentiation (Id1, Id2, Id3, and Id4) in Sertoli cells. *Endocrinology* 142:1727–1736 (2001).
- Cortes D, Thorup JM, Lindenberg S: Fertility potential after unilateral orchiopexy: Simultaneous testicular biopsy and orchiopexy in a cohort of 87 patients. *J Urol* 155:1061–1065 (1996).
- Czaplicki M, Bablok L, Janczewski Z: Fertility after treatment of bilateral cryptorchidism. *Int Urol Nephrol* 6:259–261 (1974).
- Deutsch EW, Ball CA, Berman JJ, Bova GS, Brazma A, et al: Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). *Nat Biotechnol* 26:305–312 (2008).
- Duvie SOA: Histological changes in the testis following adult orchidopexy for unilateral cryptorchidism. *Arch Androl* 12:231–234 (1984).
- Eisenhut L, Hohenfellner R: The late results of the treatment of cryptorchidism and the resulting consequences for preventive medicine. *Ann Paediatr* 203:157–163 (1964).
- Fagerli J, Schneck FX, Lee PA, Bellinger MF, Witchel SF: Absence of microdeletions in the Y chromosome in patients with a history of cryptorchidism and azoospermia or oligospermia. *Fertil Steril* 7:697–700 (1999).
- Fedder J, Crüger D, Oestergaard B, Petersen GB: Etiology of azoospermia in 100 consecutive nonvasectomised men. *Fertil Steril* 82:1463–1464 (2004).
- Gatta V, Raicu F, Ferlin A, Antonucci I, Scioletti AP, et al: Testis transcriptome analysis in male infertility: new insight on the pathogenesis of oligo-azoospermia in cases with and without AZFc microdeletion. *BMC Genomics* 11:401–410 (2010).
- Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al: Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol* 5:R80 (2004).
- Giarola A, Agostini G: Undescended testis and male fertility, in Bierich JR, Giarola A (eds): *Cryptorchidism*, pp 533–536 (Academic Press, London 1979).
- Gracia J, Sanchez Zalabardo J, Sanchez Garcia J, Garcia C, Ferrandez A: Clinical, physical, sperm and hormonal data in 251 adults operated on for cryptorchidism in childhood. *BJU Int* 85:1100–1103 (2000).
- Guillon G: Frequency and causal relationship of prepubertal cryptorchidism in male hypofertility, in Bierich JR, Giarola A (eds): *Cryptorchidism*, pp 505–516 (Academic Press, London 1979).
- Hadziselimovic F: Early successful orchidopexy does not prevent from developing azoospermia. *Int Braz J Urol* 32:570–573 (2006).
- Hadziselimovic F, Herzog B: The importance of both an early orchidopexy and germ cell maturation for fertility. *Lancet* 358:1156–1157 (2001).
- Hadziselimovic F, Hoecht B: Testicular histology related to fertility outcome and postpubertal hormonal status in cryptorchidism. *Klin Pädiatr* 219:1–6 (2008).
- Hadziselimovic F, Zivkovic D: Is the prohibition of hormonal treatment for cryptorchidism, as suggested by the Nordic consensus group, justifiable? *Acta Paediatr* 96:1368–1369 (2007).
- Hadziselimovic F, Herzog B, Girard J: Lack of germ cells and endocrinology in cryptorchid boys from one to six years of life, in Bierich JR, Giarola A (eds): *Cryptorchidism*, pp 129–134 (Academic Press, London 1979).
- Hadziselimovic F, Thommen L, Girard J, Herzog B: The significance of postnatal gonadotropin surge for testicular development in normal and cryptorchid testes. *J Urol* 136:274–276 (1986).
- Hadziselimovic F, Emmons LR, Buser MW: A diminished postnatal surge of Ad spermatogonia in cryptorchid infants is additional evidence for hypogonadotropic hypogonadism. *Swiss Med Wkly* 134:381–384 (2004).
- Hadziselimovic F, Zivkovic D, Bica DT, Emmons LR: The importance of mini-puberty for fertility in cryptorchidism. *J Urol* 174:1536–1539 (2005).
- Hadziselimovic F, Hoecht B, Herzog B, Buser MW: Infertility in cryptorchidism is linked to the stage of germ cell development at orchidopexy. *Horm Res* 68:46–52 (2007).
- Hadziselimovic F, Hadziselimovic NO, Demougin P, Krey G, Hoecht B, et al: *EGR4* is a master gene responsible for fertility in cryptorchidism. *Sex Dev* 3:253–263 (2009).
- Hamza AF, Elrahim M, Elnagar Maaty SA, Bassiouny E, et al: Testicular descent: when to interfere? *Eur J Pediatr Surg* 11:173–176 (2001).
- Hansen TS: Fertility in operatively treated and untreated cryptorchidism. *Proc R Soc Med* 42:645–651 (1949).
- Huff DS, Wu HY, Snyder HM 3rd, Hadziselimovic F, Blythe B, et al: Evidence in favor of the mechanical (intrauterine torsion) theory over the endocrinopathy (cryptorchidism) theory in the pathogenesis of testicular agenesis. *J Urol* 146:630–631 (1991).
- Hutanemi I: Gonadotrophin action on the testis – genotypes and phenotypes of gonadotrophin and gonadotrophin receptor mutations, in Söder O (ed): *The Developing Testis. Physiology and Pathophysiology*. *Endocr Dev*, Vol 5, pp 81–103 (Karger, Basel 2003).

- Ikawa M, Nakanishi T, Yamada S, Wada I, Kominami K, et al: Calmegin is required for fertilin alpha/beta heterodimerization and sperm fertility. *Dev Biol* 240:254–261 (2001).
- Inoue N, Hess KD, Moreadith RW, Richardson LL, Handel MA, et al: New gene family defined by MORC, a nuclear protein required for mouse spermatogenesis. *Hum Mol Genet* 8:1201–1207 (1999).
- Itoh N, Kayama F, Tatsuki TJ, Tsukamoto T: Have sperm counts deteriorated over the past 20 years in healthy, young Japanese men? Results from the Sapporo area. *J Androl* 22:40–44 (2001).
- Jeong DG, Cho YH, Yoon TS, Kim JH, Ryu SE, et al: Crystal structure of the catalytic domain of human DUSP5, a dual specificity MAP kinase protein phosphatase. *Proteins* 66:253–258 (2007).
- Job JC, Toubanc JE, Chaussain JL, Gendrel D, Roger M, et al: The pituitary-gonadal axis in cryptorchid infants and children. *Eur J Pediatr* 146 Suppl 2:2–5 (1987).
- Kerrien S, Alam-Faruque Y, Aranda B, Bancarz I, Bridge A, et al: IntAct-open source resource for molecular interaction data. *Nucleic Acids Res* 35:561–565 (2007).
- Kleinteich B, Schreiber G, Schickedanz H, Meyer J: Late spermatological results in surgically treated cryptorchidism. *Arztl Jugendkd* 67:173–178 (1976).
- Kovanen P, Rosenwald A, Fu J, Hurt E, Lam L, et al: Analysis of gamma c-family cytokine target genes. Identification of dual specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. *J Biol Chem* 278:5205–5213 (2003).
- Kuroda-Kawaguchi T, Skaletsky H, Brown LG, Minx PJ, Cordum HS, et al: The AZFc region of the Y chromosome features massive palindromes and uniform recurrent deletions in infertile men. *Nat Genet* 29:279–286 (2001).
- Madersbacher H, Kövesdi S, Frick J: Fertility in unilateral cryptorchidism. *Urologe A* 11:210–212 (1972).
- Mandat KM, Wieczorkiewicz B, Gubała-Kacała M, Sypniewski J, Bujok G: Semen analysis of patients who had orchidopexy in childhood. *Eur J Pediatr Surg* 4:94–97 (1994).
- Moretti E, Di Cairano G, Capitani S, Scapigliati G, Baccetti B, et al: Cryptorchidism and semen quality: a TEM and molecular study. *J Androl* 28:194–199 (2007).
- Nistal M, Paniagua R: Occurrence of primary spermatocytes in the infant and child testis. *Andrologia* 16:532–536 (1984).
- Norton JD, Deed RW, Craggs G, Sablitzky F: Id helix-loop-helix proteins in cell growth and differentiation. *Trends Cell Biol* 8:58–65 (1998).
- Okuyama A, Nonomura N, Nakamura M, Namiaki M, Fujioka H, et al: Surgical management of undescended testis: retrospective study of potential fertility in 274 cases. *J Urol* 142:749–751 (1989).
- Paasch U, Thieme C, Grunewald S, Glander HJ: Electronic data base systems support the evaluation of male infertility factors, example cryptorchidism. *Urol Int* 72:154–161 (2004).
- Paniagua R, Nistal M: Morphological and histometric study of human spermatogonia from birth to the onset of puberty. *J Anat* 139:535–552 (1984).
- Parkinson H, Kapushesky M, Shojatalab M, Abeygunawardena N, Coulson R, et al: ArrayExpress—a public database of microarray experiments and gene expression profiles. *Nucleic Acids Res* 35:747–750 (2007).
- Ponchiatti R, Grechi G: Fertility in unilateral cryptorchidism: review of 104 cases. *Acta Eur Fertil* 17:277–278 (1986).
- Puri P, O'Donnell B: Semen analysis of patients who had orchidopexy at or after seven years of age. *Lancet* 2:1051–1052 (1988).
- Raymond CS, Murphy MW, O'Sullivan MG, Bardwell VJ, Zarkower D: *Dmrt1*, a gene related to worm and fly sexual regulators, is required for mammalian testis differentiation. *Genes Dev* 14:2587–2595 (2000).
- Reynolds N, Collier B, Bingham V, Gray NK, Cooke HJ: Translation of the synaptonemal complex component Sycp3 is enhanced in vivo by the germ cell specific regulator Dazl. *RNA* 13:974–981 (2007).
- Richter W, Pröschold M, Butenandt O, Knorr D: Fertility after treatment with HCG for undescended testes. *Klin Wochenschr* 54:467–473 (1976).
- Scott LS: Unilateral cryptorchidism: subsequent effects on fertility. *J Reprod Fertil* 2:54–60 (1961).
- Seguchi H, Hadziselimovic F: [Ultramicroscopic studies on the seminiferous tubule in children from birth to puberty. I. Spermatogonia development]. *Verh Anat Ges* 68:133–148 (1974).
- Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis antigens, gametogenesis and cancer. *Nat Rev Cancer* 5:615–625 (2005).
- Siomi MC, Mannen T, Siomi H: How does the royal family of Tudor rule the PIWI-interacting RNA pathway? *Genes Dev* 24:636–646 (2010).
- Smith JM, Bowles J, Wilson M, Teasdale RD, Koopman P: Expression of the tudor-related gene *Tdrd5* during development of the male germline in mice. *Gene Expr Patterns* 4:701–705 (2004).
- Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, et al: BioGRID: a general repository for interaction datasets. *Nucleic Acids Res* 34:535–539 (2006).
- Stuppia L, Gatta V, Calabrese G, Guanciali Franchi P, Morizio E, et al: A quarter of men with idiopathic oligo-azoospermia display chromosomal abnormalities and microdeletions of different types in interval 6 of Yq11. *Hum Genet* 102:566–570 (1998).
- Taskinen S, Hovatta O, Wikström S: Early treatment of cryptorchidism, semen quality and testicular endocrinology. *J Urol* 156:82–84 (1996).
- Toppari J, Kaleva M, Virtanen HE, Main KM, Skakkebaek NE: Luteinizing hormone in testicular descent. *Mol Cell Endocrinol* 269:34–37 (2007).
- Trsinar B, Muravec UR: Fertility potential after unilateral and bilateral orchidopexy for cryptorchidism. *World J Urol* 27:513–519 (2009).
- Virtanen HE, Cortes D, Rajpert-De Meyts E, Ritzen EM, Nordenskjöld A, et al: Development and descent of the testis in relation to cryptorchidism. *Acta Paediatr* 96:622–627 (2007).
- Vogt PH: Azoospermia factor (AZF) in Yq11: towards a molecular understanding of its function for human male fertility and spermatogenesis. *Reprod Biomed Online* 10:81–93 (2005).
- von Kopylow K, Kirchhoff C, Jezek D, Schulze W, Feig C, et al: Screening for biomarkers of spermatogonia within the human testis: a whole genome approach. *Hum Reprod* 25:1104–1112 (2010).
- Vutyavanich T, Piromlertamorn W, Sirirungsri W, Sirisukkasem S: Frequency of Y chromosome microdeletions and chromosomal abnormalities in infertile Thai men with oligozoospermia and azoospermia. *Asian J Androl* 9:68–75 (2007).
- Watson ML, Zinn AR, Inoue N, Hess KD, Cobb J, et al: Identification of *morc* (microorchidia), a mutation that results in arrest of spermatogenesis at an early meiotic stage in the mouse. *Proc Natl Acad Sci USA* 95:14361–14366 (1998).
- Werder EA, Illig R, Torresani T, Zachmann M, Baumann P, et al: Gonadal function in young adults after surgical treatment of cryptorchidism. *Br Med J* 4:1357–1359 (1976).
- Wettenhall JM, Smyth GK: limmaGUI: a graphical user interface for linear modeling of microarray data. *Bioinformatics* 20:3705–3706 (2004).
- Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese KE: Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res* 35:5–12 (2007).
- Wojciechowski K, Rucki T, Sobzynski S, Szymczynski A: Long-term follow-up study of surgical treatment of cryptorchidism, in Bie-reich JR, Giarola A (eds): *Cryptorchidism*, pp 557–562 (Academic Press, London 1979).
- Wu X, Schmidt JA, Avarbock MR, Tobias JW, Carlson CA, et al: Prepubertal human spermatogonia and mouse gonocytes share conserved gene expression of germ line stem cell regulatory molecules. *Proc Natl Acad Sci USA* 22:21672–21677 (2009).
- Yang B, Yuan JL, Gao XK, Qin WJ, Liu F, et al: Expression of cell cycle molecules in human azoospermic testes. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi* 25:393–395 (2009).
- Yen PH: Putative biological functions of the DAZ family. *Int J Androl* 27:125–129 (2004).